Table 1 Patient demographics

Gender (male/female)

Age, median (range)

69

(38–84)

69

(38–84)

Albumin (g/dL)

4

(3.7–4.2)

4

(3.7–4.2)

Aspartate aminotransferase (U/L)

24

(19–30)

25

(19–33)

Alanine aminotransferase (U/L)

21

(15–28.5)

20

(14–29)

Serum creatinine (mg/dL)

0.61

(0.51–0.76)

0.63

(0.52–0.80)

Total bilirubin (mg/dL)

0.5

(0.4–0.7)

0.5

(0.4–0.6)

C-reactive protein (CRP, mg/dL)

0.3

(0.06–1.13)

0.22

(0.08–0.65)

Neutrophils (/μL)

2570

(1735–3298)

2510

(1760–3480)

White blood cells (/μL)

4250

(3155–5255)

4400

(3485–5905)

Hemoglobin (g/dL)

10.6

(9.9–11.5)

10.6

(9.7–116)

Platelets (/μL)

17.5

(12.6–26.1)

18.95

(12.9–29.3)

Neutrophil/lymphocyte ratio (NLR)

1.91

(1.41–3.18)

1.99

(1.39–3.12)

Modified Glasgow prognostic score (mGPS, 0/1/2)

Carcinoembryonic antigen (CEA, ng/mL)

6.2

(2.7–9.7)

4.6

(2.8–8.3)

Carbohydrate antigen 19–9 (CA19–9, U/mL)

655.1

(54.0–2691)

166.1

(39.8–1228)

 FOLFIRINOX

20

(33.9%)

179

(37.7%)

 Gemcitabine plus nab-paclitaxel (GnP)

27

(45.8%)

227

(47.8%)

 Gemcitabine monotherapy

12

(20.3%)

69

(14.5%)

 1st line chemotherapy

44

(74.6%)

378

(79.6%)

 2nd line chemotherapy

10

(16.9%)

68

(14.3%)

 3rd line chemotherapy

2

(3.4%)

13

(2.7%)

 Preoperative adjuvant chemotherapy

1

(1.7%)

14

(2.9%)

 Postoperative adjuvant chemotherapy

2

(3.4%)

2

(0.4%)

Time from start of first-line chemotherapy (days)

71

(35.5–253.5)

220

(112–386)

Distant metastasis, N (%)

43

(72.9%)

356

(74.9%)

Recurrent cancer, N (%)

15

(25.4%)

155

(32.6%)